Due to the significant impact of ivacaftor therapy in eligible patients in terms of ppFEV1, weight gain, and concentration of sweat chloride and to the presence of CFTR in monocytes, macrophages, and neutrophils, the literature has shown a growing interest in the role of ivacaftor on the activity of CF phagocytes [114,115,116,117]. The gene discussed is CFTR; the disease is cystic fibrosis.